13F Holdings
中文EN

BYSI BeyondSpring Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1677940 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7,733.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA185.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.2%
Debt / equity0.00x
Current ratio0.28x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.35x
Accruals ratio250.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0$0$1.35M$1.35M
R&D expense$4.39M$2.64M$7.27M$25.58M$36.89M
SG&A expense$4.56M$6.11M$7.81M$13.01M$30.70M
Operating income-$8.95M-$8.75M-$15.08M-$37.24M-$66.24M
Interest expense———$17,000$87,000
Pretax income-$8.62M-$8.77M-$13.92M-$36.12M-$64.64M
Income tax$90,000$96,000-$92,000$163,000$3.57M
Net income-$1.01M-$11.12M-$21.03M-$33.28M-$64.18M
EBITDA-$8.86M-$8.47M-$14.78M-$37.01M-$66.18M
EPS (basic)-0.02-0.28-0.54-0.85-1.64
EPS (diluted)————-1.64
Weighted avg. shares (diluted)————39.02M
Balance sheet
Cash & equivalents$2.97M$2.00M$15.34M$27.52M$41.62M
Short-term investments$1.00M$0$193,000$2.87M$30.74M
Current assets$20.88M$28.58M$18.42M$38.52M$75.12M
PP&E, net$155,000$239,000$317,000$1.87M$1.42M
Total assets$25.93M$34.31M$24.81M$46.22M$81.65M
Current liabilities$13.58M$11.01M$7.96M$7.35M$15.15M
Short-term debt———$0$1.57M
Long-term debt————$0
Total debt————$1.57M
Total liabilities$49.92M$48.60M$48.27M$49.23M$55.27M
Shareholders' equity-$32.16M-$32.90M-$26.80M-$5.98M$26.68M
Net debt————-$40.06M
Shares outstanding41.12M40.32M39.03M39.00M38.93M
Cash flow statement
Operating cash flow-$19.77M-$16.44M-$16.47M-$27.46M-$47.24M
Capital expenditure$50,000$224,000$100,000$34,000$2.84M
Free cash flow-$19.82M-$16.67M-$16.57M-$27.50M-$50.09M
Investing cash flow$10.79M-$12.01M-$100,000$17.56M-$20.41M
Financing cash flow$4.97M$26.79M$4,000$3.43M$1,000
Depreciation & amortization$87,000$285,000$302,000$232,000$61,000
Stock-based compensation$722,000$2.25M$770,000$1.67M$3.15M

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.